[Benefit assessment of PET in malignant lymphomas: the IQWiG point of view]

Scheibler, F. and Raatz, H. and Suter, K. and Janssen, I. and Grosselfinger, R. and Schröer-Günther, M. and Kunz, R. and Lange, S.. (2010) [Benefit assessment of PET in malignant lymphomas: the IQWiG point of view]. Nuklearmedizin, Vol. 49, H. 1. pp. 1-5.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6003335

Downloads: Statistics Overview


The call by the Institute for Quality and Efficiency in Health Care (IQWiG) for randomised controlled trials (RCTs) to prove the patient-relevant benefit of positron emission tomography (PET) is currently a controversial topic in Germany. From a methodological point of view there is essentially no difference between diagnostic procedures and therapeutic (drug or non-drug) interventions in proving their causal benefit. A broad consensus has been reached since the 1960s (e.g. FDA regulations) that RCTs are the methodological gold standard for therapeutic interventions. Nevertheless, the same arguments that were cited against RCTs in assessing the benefit of therapeutic interventions are now used against RCTs in evaluating diagnostic tests (e.g. ethical problems, feasibility, etc.). This paper summarizes the central methodological arguments of the discussion on the benefit assessment of PET in malignant lymphomas from the perspective of IQWiG and its external experts.
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Versicherungsmedizin > Versicherungsmedizin (Kunz)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Versicherungsmedizin > Versicherungsmedizin (Kunz)
UniBasel Contributors:Kunz, Regina
Item Type:Article, refereed
Article Subtype:Research Article
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:24 May 2013 09:12
Deposited On:26 Apr 2013 06:56

Repository Staff Only: item control page